News

2019 News & Events

Senate Finance Committee to Question PBMs
April 8, 2019 — The Senate Finance Committee will question Pharmacy Benefit Managers, whose role isn't always clear. "PBMs have saved money over the last decade by encouraging use of generics," CP3 Director Walid Gellad told NPR. Read More »
CP3 Research Part of Drug Pricing Conversation
April 8, 2019 — Our research contributes to conversations about drug pricing. The Pittsburgh Post-Gazette mentioned a recent Health Affairs paper by Dr. Inma Hernandez and Dr. Walid Gellad. Read More »
Memorial Sloan Kettering Revises Conflict of Interest Policies After Scandal
April 4, 2019 — Memorial Sloan Kettering revised its conflict of interest policies after officials violated them last year. “Memorial Sloan Kettering really does seem to be taking this seriously and this document, I think, shows it,” CP3 Director Walid Gellad told the New York Times. Read More »
Hernandez Talks Insulin Prices on Nightly Business Report
April 3, 2019 — Associate Director Dr. Inma Hernandez appeared on CNBC's Nightly Business Report to discuss Cigna's announcement about copayment reductions for insulin. Hernandez notes that while this is a step in the right direction, she feels that list prices should be lowered. Read More »
Health IT Analytics Touts CP3 Machine Learning Study
March 25, 2019 — “Machine learning models that use administrative data appear to be a valuable and feasible tool for identifying more accurately and efficiently individuals at high risk of opioid overdose," notes CP3 Director Walid Gellad. Health IT Analytics featured new work published in JAMA Network Read More »
Drug Price Proposals "Revolutionary," Notes Gellad
March 22, 2019 — "The competition between companies has been on how big a rebate they can give," CP3 Director Walid Gellad told NPR's Alison Kodjak, "and the way that you give a big rebate is by increasing the list price. So the idea is to get rid of that so that companies can compete based on getting the Read More »
Hernandez Inducted as ACC Fellow
March 20, 2019 — CP3 Associate Director Dr. Inma Hernandez has received yet another honor in recognition for her research and professional achievements. She has been inducted as a Fellow in the American College of Cardiology at its 68th Annual Scientific Session and Expo. Read More »
Hernandez Receives Rho Chi Award
March 19, 2019 — CP3 Assoicate Director Dr. Inma Hernandez has added another award to her growing list of accomplishments. She was awarded the Rho Chi Society Outstanding Scholarly Contribution Award. Rho Chi is the academic honor society in pharmacy, and the award is Hernandez's first student-voted award Read More »
Hernandez Predicts Outcome of Proposed Rebate Rule
March 18, 2019 — CP3 Associate Director Dr. Inma Hernandez joins Dr. Stacie Dusetzina and Dr. Peter Bach in predicting what might happen under proposed changes in drug rebates, in Politico's Prescription Pulse. Hernandez said that list prices would need to drop in order for insurance plan premiums to stay Read More »
Link between Drug Shortages and Price Increases a "Battle," Hernandez Tells CNN
March 12, 2019 — An FDA approval of generic valsartan may relieve a shortage of the drug, but as CP3 Associate Director Dr. Inma Hernandez told CNN Health, drug shortages are often linked to price increases. "The place where we have to win this battle to prevent further price increases is in Congress," she Read More »
Veterans with Dual Receipt of Opioid Prescriptions at Increased Risk of Overdose
March 11, 2019 — CP3 Director Walid Gellad is an author on a new Annals of Internal Medicine paper showing veterans with dual receipt of opioid prescriptions from the VA and Medicare Part D are 3.5 times as likely to die from overdose. In an article in US News and World Report, Gellad discusses the paper's Read More »
Hernandez Puts Lilly's Half Price Insulin in Perspective
March 10, 2019 — "There's no justification for why prices should keep increasing at an average rate of 10 percent every year," CP3 Associate Director Dr. Inma Hernandez told NPR about rising insulin prices. The NPR piece provided background on insulin prices and put into perspective Eli Lilly's recent Read More »
Gellad Discusses High Drug Costs on MPR
March 5, 2019 — CP3 Director Walid Gellad was a guest on Minnesota Public Radio, joining David Mitchell, the founder of the advocacy group Patients for Affordable Drugs, as well as a representative from PhRMA. The group discussed the rising costs of prescription drugs and took calls from listeners who Read More »
Most Postoperative Patients Have Unused Opioids
March 5, 2019 — Two recent studies share findings that the majority of certain postoperative patients have unused opioids, reports Urology Times. One of the studies is a paper co-authored by CP3 affiliated faculty Dr. Ben Davies, showing that 60% of opioids prescribed to prostate or kidney surgery Read More »
Gottlieb's Resignation a "Big Loss"
March 5, 2019 — FDA Commissioner Scott Gottlieb's resignation comes as a shock to many. "I see this is a big loss for the administration's efforts to address drug pricing," CP3 Director Walid Gellad told BioPharma Dive. Read More »
Hernandez Comments on KFF Poll Showing Americans Believe Drug Prices Are Too High
March 1, 2019 — "Financial barriers for medication use are not rare, and they can actually have and are having, a detrimental effect on our fellow citizens' health," CP3 Associate Director Dr. Inma Hernandez told NPR. Hernandez's comments are in response to a Kaiser Family Foundation poll showing that 79 Read More »
Pruskowski's Polypharmacy Study Highlighted
February 28, 2019 — The unintended consequences of polypharmacy are gaining more attention. This paper co-authored by CP3 affiliated faculty Dr. Jennifer Pruskowski shows why. This work was also highlighted by UPMC. Read More »
Essien Named to 40 Under 40 Minority Health Leaders
February 27, 2019 — Dr. Utibe Essien, CP3 affiliated faculty member, had the honor of being named one of the National Minority Forum's 40 Under 40 Leaders in Minority Health. Dr. Essien joins a list of other leaders whose work aims to reduce health disparities among minorities. Read More »
Gellad's Tweet Quoted in Washington Post
February 26, 2019 — CP3 Director Dr. Walid Gellad had a tweet quoted in a Washington Post piece on the Congressional drug pricing hearings. Read More »
Dr. Utibe Essien on Review of Systems Podcast
February 25, 2019 — CP3 affiliated faculty member Dr. Utibe Essien was a guest on Harvard's Center for Primary Care's podcast "Review of Systems". Dr. Essien spoke about his recent JAMA Cardiology paper and its relationship to the podcast episode's theme of racism in medicine. To listen, click here. Read More »
Drug Pricing Movement is Growing, Gellad Tells Houston Chronicle
February 25, 2019 — There is a growing push to limit rising drug costs. “Everything seems to be aligning for something to happen on drug pricing," CP3 Director Dr. Walid Gellad told the Houston Chronicle. Read More »
Hernandez's Work Discussed in Context of "Opportunistic Behavior" in Drug Pricing
February 20, 2019 — Pharmalot discusses Dr. Inma Hernandez's recent JAMA Internal Medicine letter on trends in drug prices and spending for TNF inhibitors in 2006-2016, and the opportunistic behavior to raise prices that the team's findings suggest. Read More »
Davies Comments on Cancer Drug Shortage
February 20, 2019 — Supplies of BCG, an effective bladder cancer drug, are running low, and worry is running high. "There’s very little incentive, outside of altruism, to make this better,” CP3 affiliated faculty Dr. Ben Davies told STAT News. Read More »
"Everyone is at fault" for Rising Insulin Prices
February 19, 2019 — “Everyone is at fault, which makes it hard to figure out how to fix it,” CP3 Director Dr. Walid Gellad told STAT News about rising insulin prices. Read More »
Inma Hernandez Is Guest on Plenary Session
February 18, 2019 — CP3 Associate Director Dr. Inma Hernandez was interviewed by Dr. Vinay Prasad on his Plenary Session podcast about rising drug costs and other policy issues. Listen here (starting ~36:45). Read More »
Walid Gellad Is Guest on Texas Public Radio
February 5, 2019 — CP3 Director Walid Gellad was a guest on Texas Public Radio's live call in program "The Source," along with Washington Post reporter Amy Goldstein. Dr. Gellad and Ms. Goldstein gave their thoughts and answered questions about proposed changes to phase out prescription drug rebates. Click Read More »
Gellad Tells Axios About Relationship Between Transparency and Drug Pricing
February 4, 2019 — CP3 Director Walid Gellad spoke with Axios about the relationship between transparency and drug pricing. "Transparency can help the public and policy makers make more informed decisions about what to do about high drug prices - who to target, what policies to put in place...Just the Read More »
Elimination of Drug Rebates a "Huge Potential Change," Gellad Tells NPR
February 1, 2019 — "This is a huge potential change, transformative," CP3 Director Walid Gellad told Alison Kodjak of NPR in response to an HHS proposal to eliminate drug rebates for middlemen. Read More »
Inma Hernandez Featured in Pittwire
January 31, 2019 — CP3 Associate Director Inma Hernandez was featured in the January 31st edition of Pittwire, the University of Pittsburgh's news service. The article discusses Dr. Hernandez's recent publication examining the drivers of rising drug prices. Read More »
Gellad Speaks to CNN About Drug Pricing in the 2020 Election
January 24, 2019 — Everything is up in the air and anything is possible," CP3 Director Walid Gellad told Kaiser Health News via CNN Health in response to potential drug pricing proposals by Democrats in the 2020 election. Dr. Gellad added, "There are things that can happen that maybe weren't going to happen Read More »
Hernandez Talks Drug Price Drivers on FOX News
January 22, 2019 — Inma Hernandez, CP3 Associate Director, appeared on Fox News, discussing her recent Health Affairs paper on drivers of rising drug prices. Her appearance was part of a larger story on pharmaceutical prices. Read More »
Inma Hernandez Talks Drug Pricing on WESA
January 14, 2019 — “Pharmaceutical manufacturers realize our health care system is very fragmented, and payers don’t have, in many cases, much leverage,” CP3 Associate Director Inma Hernandez told WESA-FM's Sarah Boden. “So, they take advantage of that.” Hernandez spoke with Boden about a drug pricing study Read More »
CNBC Interviews Hernandez About Drug Pricing Study
January 14, 2019 — "Rising drug prices affect uninsured or underinsured patients, patients with high-deductible plans, those in the deductible or doughnut hole phase of their plans, the government as a payer, and all Americans in the form of higher premiums," CP3 Associate Director Inma Hernandez told CNBC. Read More »
Hernandez Drug Pricing Study Cited in News Story
January 13, 2019 — The recent drug-pricing study led by CP3 Associate Director Inma Hernandez was cited in an ABC News piece about rising drug prices. Read More »
Gellad Calls COI Policy Changes a Watershed Moment
January 11, 2019 — CP3 Director Walid Gellad spoke with the New York Times and ProPublica about significant changes in Sloan Kettering's conflict of interest policy after a scandal last year. Gellad called the changes a "watershed moment." Read More »
Study Quantifies Drug Price Increases
January 7, 2019 — A study led by CP3 Associate Director Inma Hernandez shows how much drug list prices are increasing compared to inflation.  STAT Plus reports on the findings. Read More »
CP3 Associate Director Inma Hernandez Discusses Drug Cost Drivers
January 7, 2019 — "The main takeaway of our study should be that increases in prices of brand-name drugs were largely driven by year-over-year price increases of drugs that were already in the market," CP3 Associate Director Inma Hernandez, PharmD, PhD, told NPR's Alison Kodjak. Kodjak reported on a recent Read More »